These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 22454535

  • 1. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF.
    J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
    Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF.
    J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
    [Abstract] [Full Text] [Related]

  • 6. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.
    Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF.
    Drug Metab Dispos; 2014 Aug; 42(8):1292-300. PubMed ID: 24875464
    [Abstract] [Full Text] [Related]

  • 7. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF.
    J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
    [Abstract] [Full Text] [Related]

  • 8. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.
    Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF.
    Drug Metab Dispos; 2018 May; 46(5):658-666. PubMed ID: 29437873
    [Abstract] [Full Text] [Related]

  • 9. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
    [Abstract] [Full Text] [Related]

  • 10. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.
    Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
    [Abstract] [Full Text] [Related]

  • 11. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
    Wu CP, Sim HM, Huang YH, Liu YC, Hsiao SH, Cheng HW, Li YQ, Ambudkar SV, Hsu SC.
    Biochem Pharmacol; 2013 Feb 01; 85(3):325-34. PubMed ID: 23153455
    [Abstract] [Full Text] [Related]

  • 12. Acquired and intrinsic resistance to vemurafenib in BRAFV600E -driven melanoma brain metastases.
    Zhang P, Kuil LE, Buil LCM, Freriks S, Beijnen JH, van Tellingen O, de Gooijer MC.
    FEBS Open Bio; 2024 Jan 01; 14(1):96-111. PubMed ID: 37953496
    [Abstract] [Full Text] [Related]

  • 13. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M, Khurana V, Qin B, Pal D, Mitra AK.
    Int J Pharm; 2012 Sep 15; 434(1-2):306-14. PubMed ID: 22633931
    [Abstract] [Full Text] [Related]

  • 14. Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.
    Michaelis M, Rothweiler F, Nerreter T, van Rikxoort M, Zehner R, Dirks WG, Wiese M, Cinatl J.
    BMC Res Notes; 2014 Oct 10; 7():710. PubMed ID: 25300205
    [Abstract] [Full Text] [Related]

  • 15. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
    Wang T, Agarwal S, Elmquist WF.
    J Pharmacol Exp Ther; 2012 May 10; 341(2):386-95. PubMed ID: 22323823
    [Abstract] [Full Text] [Related]

  • 16. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K, Wanek T, Bankstahl M, Bankstahl JP, Fedrowitz M, Müller M, Löscher W, Kuntner C, Langer O.
    Nucl Med Biol; 2013 Oct 10; 40(7):873-8. PubMed ID: 23845421
    [Abstract] [Full Text] [Related]

  • 17. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
    Minocha M, Khurana V, Qin B, Pal D, Mitra AK.
    Int J Pharm; 2012 Oct 15; 436(1-2):127-34. PubMed ID: 22688250
    [Abstract] [Full Text] [Related]

  • 18. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
    Liu X, Cheong J, Ding X, Deshmukh G.
    Drug Metab Dispos; 2014 Apr 15; 42(4):482-91. PubMed ID: 24398459
    [Abstract] [Full Text] [Related]

  • 19. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ, Milton MN, Yu S, Liao M, Liu N, Wu JT, Gan L, Balani SK, Lee FW, Prakash S, Xia CQ.
    Drug Metab Lett; 2010 Dec 15; 4(4):201-12. PubMed ID: 20670210
    [Abstract] [Full Text] [Related]

  • 20. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
    Agarwal S, Sane R, Ohlfest JR, Elmquist WF.
    J Pharmacol Exp Ther; 2011 Jan 15; 336(1):223-33. PubMed ID: 20952483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.